Press

Drug discovery technology start-up DyNAbind secures seed financing

May 7, 2019

DyNAbind’s Dynamic DNA-Encoded Library technology platform allows hundreds of millions of chemical structures to be simultaneously screened and optimized against a potential drug target protein. This innovation continues to be driven forward with investment from the High-Tech Gründerfonds (HTGF), Technologiegründerfonds Sachsen (TGFS) and existing shareholder TUDAG – TU Dresden AG.

Finding a new drug candidate can be like finding a needle in a haystack. Imagine that instead of checking one straw at a time, you had a magnet that could search the haystack all at once. DyNAbind is offering that magnet in the form of their proprietary Dynamic DNA-Encoded Library (D-DEL) technology platform. Chemical structures are tagged with unique barcodes made from DNA and mixed together. This library of chemicals is then simultaneously screened against a drug target protein of interest. D-DEL technology delivers results at over ten times the speed of classical discovery methods.

The complexity of modern drug targets has driven demand for robust, reliable discovery technologies with minimized risk. DyNAbind partners with pharma, biotech and academic organizations to meet these needs. The company has already publicly announced deals with groups including SoseiHeptares, Northwestern University Chicago and OMass Therapeutics. A DEL discovery kit is also offered in partnership with Merck KGaA (MilliporeSigma in the US).

DyNAbind co-founder and CEO Mike Thompson is looking forward to putting this investment to good use. “It’s exciting for us to have closed this financing round. HTGF and TGFS have a strong track record in Germany, and we’re honoured that TUDAG has chosen to invest in DyNAbind for a second time. These funds will allow us to build up a new, larger lab space and expand our team to meet the increasing demand we’re getting from the market.”

Fabian Mohr, Investmentmanager at High-Tech Gründerfonds, summarizes their investment thesis: “DyNabind’s technology solves many obstacles of conventional offerings in the current market. We are convinced that the patented dynamic library design and the current selection of fragments and small-molecules in a favourable chemical space will strongly enable DyNabind to grow their business and create value for their customers.”

About DyNAbind
DyNAbind is a Dresden-based, privately held company offering drug discovery products and partnership based on its proprietary Dynamic DNA-Encoded Library (D-DEL) platform. DyNAbind is a spin-out from the lab of Prof. Yixin Zhang at the TU Dresden. Company development began in 2015 under an EXIST-Forschungstransfer grant, with foundation in 2017. For more information, visit www.dynabind.com

Press contact
Dr. Mike Thompson
info@dynabind.com

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 892.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 530 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences.

To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Contact
High-Tech Gründerfonds Management GmbH
Dr. Fabian Mohr
Schlegelstraße 2
53113 Bonn
Tel.: +49 228 82300-181
f.mohr@htgf.de
www.htgf.de

About Technologie Gründerfonds Sachsen
The TGFS (Technologiegründerfonds Sachsen, Technology Founder Fund Saxony) provides technology-oriented start-ups with equity capital in the seed and start-up phase. The fund was launched in 2008 with a volume of 60 million € and increased to more than 124 million € in March 2016. Target companies of the TGFS are young, innovative, technology-oriented founders and companies in the ITC, semiconductor and microsystems technology, medical technology, life science, environmental and energy technology and new media sectors. The TGFS is aimed at young companies based or operating in Saxony.

Contact
Technologiegründerfonds Sachsen
Tobias Voigt
Anton-Graff-Straße 20
01309 Dresden
Tel.: +49 351 44090
tobias.voigt@tgfs.de  
www.tgfs.de

About TU Dresden AG (TUDAG)
TUDAG – TU Dresden AG is a profit-oriented company based in Dresden with a total of over 600 employees. With more than 25 participations, it initiates and supports the transfer of knowledge and technology (primarily from the TU Dresden) to the private sector. In addition, TUDAG transports the requirements of industry to science. www.tudag.de

Contact
TUDAG – TU Dresden AG
Francisco Arroyo
Freiberger Str. 37
01067 Dresden
Tel.: +49 351 40470 302
francisco.arroyo@tudag.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Press
25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017. Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that N
 
Press
25. March 2024

Growth push for CI HUB GmbH, Catalyzing Innovation in Content Integration Solutions

Potsdam, 25.03.2024 – Scale Capital, a Danish early stage technology investor with a focus on helping companies accelerate growth in the US market, has announced its investment in CI HUB GmbH, a leading provider of content integration solutions. This significant seven-figure amount from new and existing investors marks a milestone in CI HUB’s journey towards revolutionizing the way corporates and creatives access digital assets and data. CI HUB specializes in developing innovative
 
Press
20. March 2024

graswald.ai raises $3.3M seed round to scale the way brands create 3D content with AI

The Hannover-based start-up has secured seed funding to build Canva for 3D, leveraging generative AI to transform 3D creative processes for 3D product visualisation. Hannover, 20 March 2024 – graswald.ai announced the close of a $3.3 million seed round led by existing investor Lakestar as well as Supernode Global with continued support from existing investor HTGF and further participation from Spatial Computing expert FOV Ventures, Robin Capital, Angel Invest Ventures and Notion Sc